NEWS

Blog » Poverty Linked to Longer Hospital Stay For Newborns with Opioid Withdrawal

Poverty Linked to Longer Hospital Stay For Newborns with Opioid Withdrawal

Created Jul 22 2019, 02:54 PM by Wolters Kluwer Health
  • Journal of Addiction Medicine

July 22, 2019 – For infants with neonatal opioid withdrawal syndrome (NOWS) due to prenatal opioid exposure, poverty is a risk factor for prolonged length of hospital stay, reports a study in the Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine (ASAM). The journal is published in the Lippincott portfolio by Wolters Kluwer.

"These results suggest that excess length of stay may be the result of non-medical factors linked to poverty and that early allocation of resources for at-risk families may help to reduce the overall length of stay," according to the new research by Zachary A. Vesoulis, MD, and colleagues of Washington University School of Medicine, St. Louis.

Non-Medical Factors May Explain Poverty-Related Increases in Length of Stay

The study included 129 infants at risk of NOWS treated in the newborn ICU of an urban children's hospital between 2012 and 2017. Two-thirds of infants required morphine, alone or with other medications, to treat opioid withdrawal symptoms.

Fifty-two percent of patients came from urban/suburban communities and 48 percent from rural areas. Nearly 90 percent were on public insurance. Based on family income in the mother's ZIP code, 25 percent lived in "most disadvantaged" areas with high poverty rates. Only 16 percent of patients were black, but they were more likely to live in high-poverty areas. Poverty and other factors were analyzed for association with length of hospital stay.

The median hospital stay was 16 days.  As in previous studies, infants who needed morphine treatment spent more time in the hospital: 23 versus eight days.

Poverty was strongly related to excess hospital stay: each one-point increase in the 0-to-100 Area Deprivation Index was associated with 0.13 extra days in the hospital. That was so even after controlling for morphine treatment, placement in state's custody, race, and gestational age at birth.

Race was the only other significant predictor: black infants averaged 2.8 more days in the hospital compared to white infants. "We speculate that infant race is serving as a secondary indicator of poverty," the researchers write.

While the study can't draw any conclusions about why poverty is associated with prolonged hospital stay in infants with NOWS, the researchers believe that "non-medical impediments to timely hospital discharge" play a role. "Possible barriers include lack of transportation to the hospital, inability to obtain essential infant care items such as car seats or cribs, inadequate childcare resources for other children in the home, access to postnatal care and/or medication treatment," Dr. Vesoulis and colleagues write.

They add: "Leveraging all available social services at the time of the infant's admission to improve access to the hospital and resources to care for the infant at home is a clear target for reducing length of stay."

The study is among the first to look at how poverty and other social determinants of health affect differences in hospitalization outcomes of infants with NOWS, according to an editorial by Elisha M. Wachman, MD, of Boston Medical Center. "Future studies should focus on identifying key social determinants that impact NOWS clinical course," Dr. Wachman writes. She adds that the observed racial disparities "are important to understand for designing population-level interventions in order to improve the health of these maternal-infant dyads."

Click to read "Poverty and Excess Length of Hospital Stay in Neonatal Opioid Withdrawal Syndrome"

DOI: 10.1097/ADM.0000000000000540

Click to read "How Might Maternal Poverty Impact the Course of Neonatal Opioid Withdrawal Syndrome?"

DOI: 10.1097/ADM.0000000000000541

###

About Journal of Addiction Medicine

The mission of Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine, is to promote excellence in the practice of addiction medicine and in clinical research as well as to support Addiction Medicine as a mainstream medical specialty. Published six times a year, the Journal is designed for all physicians and other mental health professionals who need to keep up-to-date with the treatment of addiction. Under the guidance of an esteemed Editorial Board, peer-reviewed articles published in the Journal focus on developments in addiction medicine as well as on treatment innovations and ethical, economic, forensic, and social topics. Visit us on the web at www.JournalAddictionMedicine.com .

 

About The American Society of Addiction Medicine

The American Society of Addiction Medicine (ASAM) is a professional society representing more than 6000 physicians, clinicians, and associated professionals in the field of addiction medicine. ASAM is dedicated to increasing access and improving the quality of addiction treatment, educating physicians and the public, supporting research and prevention, and promoting the appropriate role of physicians in the care of patients with addiction. Visit us on the web at www.ASAM.org; follow @ASAMorg on Twitter.

 

About Wolters Kluwer

Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.

Wolters Kluwer reported 2018 annual revenues of €4.3 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 18,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students with advanced clinical decision support, learning and research and clinical intelligence. For more information about our solutions, visit http://healthclarity.wolterskluwer.com and follow us on LinkedIn and Twitter @WKHealth.

For more information, visit www.wolterskluwer.com, follow us on TwitterFacebookLinkedIn, and YouTube.

Media Contacts

Connie Hughes

Director, Corporate Communications, Health Learning, Research & Practice

+1 646-674-6348​

Email

Ellen Robinson 

Public Relations & Social Media Specialist, Health Learning, Research & Practice

+1 704-962-5912

Email

Loading